Hansen Hh

679 citations
35 papers · 539 · h-index 12

Impact in

  • Oncology top 10%
    • Lung Cancer Research Studies
    • Peptidase Inhibition and Analysis
    • Lung Cancer Treatments and Mutations
    • Occupational and environmental lung diseases
    • Brain Metastases and Treatment
    • Pleural and Pulmonary Diseases

Papers in

    • Lung Cancer Research Studies 16
    • Peptidase Inhibition and Analysis 5
    • Cancer Treatment and Pharmacology 3
    • Neuroendocrine Tumor Research Advances 13

Hansen Hh

34 papers receiving 454 citations

Peers

Hansen Hh
Comparison fields: 5 of 64
  • Oncology 351
  • Pulmonary and Respiratory Medicine 247
  • Epidemiology 186
  • Neurology 40
  • Reproductive Medicine 22
Replace Eagan Rt with:
Eagan Rt United States
J. Michel Belgium
G Martz Switzerland
Franco Testore Italy
Bonnie J. Trochanowski United States
Golbey Rb United States
Federico Castiglione Italy
Brian M.J. Cantwell United Kingdom
H Karnicka-Młodkowska Poland
Ettinger Ds United States
Hansen Hh relative to Eagan Rt United States Eagan Rt's profile →
Citations per field
00.5×4.4×
Eagan Rt · 1×
Citations per year

Countries citing papers authored by Hansen Hh

Since Specialization
Citations

This map shows the geographic impact of Hansen Hh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hansen Hh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hansen Hh more than expected).

Fields of papers citing papers by Hansen Hh

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hansen Hh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hansen Hh. The network helps show where Hansen Hh may publish in the future.

Co-authors

The 25 scholars most cited alongside Hansen Hh, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Hansen Hh Line = papers co-authored together Hansen Hh links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 35 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Staging procedures and prognostic features in small cell anaplastic bronchogenic carcinoma.
197882
2
Should initial treatment of small cell carcinoma include systemic chemotherapy and brain irradiation?
197373
3
Commentary: current status of chemotherapy for non-small cell lung cancer.
198272
4
Randomized trial of doxorubicin versus cyclophosphamide in diffuse malignant pleural mesothelioma.
198567
5
Phase II study of teniposide in small cell carcinoma of the lung.
198424
6
Phase II clinical trial of VP-16-213 in ovarian cancer.
198124
7
PHASE I clinical trial of an oral solution of VP-16-213.
197623
8
Vindesine in the treatment of squamous cell carcinoma, adenocarcinoma, and large cell carcinoma of the lung.
198221
9
cis-Dichlorodiammineplatinum (II) in small cell anaplastic bronchogenic carcinoma: a phase II study.
197919
10
[DETERMINATION OF THYROID GLAND FUNCTION BY MEANS OF I-131 LABELLED 1-TRIIODOTHYRONINE AND SEPHADEX. EXAMINATIONS OF NORMAL PERSONS AND PATIENTS WITH THYREOTOXICOSIS].
196418
11
Vindesine in the treatment of small cell anaplastic bronchogenic carcinoma.
198115
12
Clinical studies with a new podophyllotoxin derivative, epipodophyllotoxin, 4'-demethyl-9-(4,6-O-2-thenylidine- -D-glucopyranoside) (NSC-122819).
197112
13
Treatment of malignant brain tumors with nitrosoureas.
197111
14
Phase II study of procarbazine in small cell carcinoma of the lung.
198211
15
Vincristine (NSC-67574) in the treatment of small-cell anaplastic carcinoma of the lung.
197611
16
Mepacrine hydrochloride in the treatment of malignant pleural effusion. A controlled randomized trial.
19778
17
Phase I clinical trial of a single-dose and two weekly schedules of ICRF-159 (NSC-129943).
19747
18
5-FU in the treatment of small cell anaplastic carcinoma of the lung: a phase II trial.
19816
19
Phase II study of vinblastine in small cell carcinoma of the lung.
19835
20
Phase II study of vindesine, cisplatin, and hexamethylmelamine (VCH) in small cell carcinoma of the lung.
19844

About Hansen Hh

Hansen Hh is a scholar working on Oncology, Epidemiology, Molecular Biology, Pulmonary and Respiratory Medicine and Neurology, having authored 35 papers that have together received 539 indexed citations. Recurring topics across this work include Lung Cancer Research Studies (16 papers), Neuroendocrine Tumor Research Advances (13 papers), Cancer therapeutics and mechanisms (6 papers), Peptidase Inhibition and Analysis (5 papers), Cancer Treatment and Pharmacology (3 papers), Pleural and Pulmonary Diseases (2 papers), Neuroblastoma Research and Treatments (2 papers) and Lung Cancer Diagnosis and Treatment (2 papers). The work is most often cited by research in Oncology (351 citations), Pulmonary and Respiratory Medicine (247 citations), Epidemiology (186 citations), Neurology (40 citations) and Reproductive Medicine (22 citations). Hansen Hh has collaborated with scholars based in Denmark and United States. Frequent co-authors include P Dombernowsky, Joseph Aisner, E Bork, Kell Østerlind, S Sörenson, Franco M. Muggia, Mikael Rørth, Kim S. Larsen, Nissen Ni and Bo Hainau. Their work appears in journals such as PubMed.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact